Janney Montgomery Scott LLC Has $2.12 Million Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Janney Montgomery Scott LLC decreased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 29.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 305,069 shares of the company’s stock after selling 127,755 shares during the period. Janney Montgomery Scott LLC owned about 0.73% of Zevra Therapeutics worth $2,117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in ZVRA. City State Bank boosted its holdings in shares of Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after purchasing an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares in the last quarter. International Assets Investment Management LLC grew its position in Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after acquiring an additional 5,940 shares during the last quarter. IFG Advisors LLC raised its stake in Zevra Therapeutics by 41.2% during the third quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after acquiring an additional 7,700 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Zevra Therapeutics by 17.9% in the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after acquiring an additional 8,619 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $8.57 on Wednesday. The stock’s 50 day moving average is $7.94 and its 200 day moving average is $6.42. Zevra Therapeutics, Inc. has a one year low of $3.89 and a one year high of $9.09. The firm has a market cap of $450.94 million, a P/E ratio of -5.10 and a beta of 1.93. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same quarter last year, the company earned ($0.15) earnings per share. As a group, research analysts expect that Zevra Therapeutics, Inc. will post -1.63 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ZVRA shares. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, September 18th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Monday, September 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Maxim Group boosted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.83.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.